For research use only. We do not sell to patients.
Ionizable lipids / 4A3-SC7​​
4A3-SC7​​ chemical structure
Product imageResearch use only
CAT. NO. DC60855Featured

4A3-SC7​​

Pack size & price

USD
TotalUS$700
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

4A3-SC7 is an ionizable lipid studied in organ-selective RNA delivery. Five-component formulations combine it with a SORT lipid to alter tissue delivery. Published evidence includes liver formulation optimization, pulmonary reporter delivery with DORI-containing LNPs, and multi-organ base-editing research.

Open full Formulation & Performance →

Literature evidence · DC60855

Formulation & Performance

The Dual SORT study uses distinct liver and lung carriers. The original lung carrier contains 5A2-SC8 and DOTAP; an updated lung carrier contains 4A3-SC7 and DORI. Results of the combined treatment are not treated as properties of 4A3-SC7 alone.

DC60855 is 4A3-SC7, not 4A3-SC8. Source nomenclature distinguishes 4A3-Cit, the additional liver SORT lipid, from the base ionizable lipid.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
4A3-SC7DC608551411.0715.040.212225
DOPEDC33634744.0323.040.171425
CholesterolDCD-041386.6538.720.149711
DMG-PEG2000DC4016925073.20.080224
4A3-Cit (Cit Liver SORT lipid)Not uniquely mappedNot established20Not calculable from disclosed data

Lead ABE liver formulation #12, Supplementary Table 3 (printed p.28; PDF p.29): 15.04:23.04:38.72:3.2:20 mol%; total lipid:RNA = 20:1 by mass. 4A3-Cit has not been uniquely mapped to a catalog product/MW, so its mass and the total mass percentage remain unassigned. N/P is not inferred.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
4A3-SC7——
DOPE——
Cholesterol——
DMG-PEG2000——
4A3-Cit (Cit Liver SORT lipid)——

Earlier liver reporter formulation — Supplementary Fig. 1

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
4A3-SC7DC608551411.0719.040.268668
DOPEDC33634744.0319.040.141663
CholesterolDCD-041386.6538.720.149711
DMG-PEG2000DC4016925073.20.080224
4A3-CitNot uniquely mappedNot established20Not calculable from disclosed data

Luciferase formulation from Supplementary Fig. 1. Its composition and particle measurements are kept separate from the optimized ABE formulation.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
4A3-SC7——
DOPE——
Cholesterol——
DMG-PEG2000——
4A3-Cit——

Updated pulmonary formulation — Supplementary Fig. 11

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
4A3-SC7DC608551411.0721.60.304791
DOPEDC33634744.03120.089284
CholesterolDCD-041386.6524.40.094343
DMG-PEG2000DC40169250720.050140
DORINot uniquely mappedNot established40Not calculable from disclosed data

4A3-SC7 / DOPE / cholesterol / DMG-PEG2000 / DORI = 21.6:12:24.4:2:40 mol%. DORI is a distinct SORT lipid; DOTAP values and the original 5A2-SC8 formulation are not substituted.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
4A3-SC7——
DOPE——
Cholesterol——
DMG-PEG2000——
DORI——

Cargo-specific liver formulation optimization

Study / parameterReported evidenceSource / interpretation
ABE formulation #119.04:19.04:38.72:3.2:20; lipid:RNA 20:1; EE 58 ± 3%; size 130 ± 41 nm; PDI 0.28 ± 0.03Supplementary Table 3; values as reported
ABE formulation #1215.04:23.04:38.72:3.2:20; lipid:RNA 20:1; EE 87 ± 5%; size 74 ± 4 nm; PDI 0.17 ± 0.02Supplementary Table 3; lead formulation
Cargo-length comparisonsgRNA: EE 91 ± 3%, 71 ± 5 nm; Cre mRNA: 89 ± 2%, 81 ± 4 nm; ABE mRNA: 48 ± 10%, 98 ± 20 nmSupplementary Table 2; a separate cargo comparison, not formulation #12 release values
N/PNot assigned from the available evidence20:1 is a total-lipid:RNA mass ratio

Liver luciferase delivery

Study / parameterReported evidenceSource / interpretation
Model and measurementC57BL/6J mice; IV luciferase mRNA 0.015 mg/kg; 6 h; n = 2 biological replicatesSupplementary Fig. 1
Five-component result1.8-fold higher potency than the four-component Cit formulationSupplementary Fig. 1c; the comparator omits 4A3-SC7
Five-component particles71 ± 0.25 nm; PDI 0.16 ± 0.007Supplementary Fig. 1a; composition shown separately above
Cit-only comparator59.6 ± 0.8 nm; PDI 0.18 ± 0.004Comparator composition and outcome are not assigned to DC60855

Pulmonary delivery with the updated DORI formulation

Study / parameterReported evidenceSource / interpretation
Reporter studyAi14 mice; Cre mRNA 0.3 mg/kg; lung analysis at 2 days; n = 3Supplementary Fig. 11
Measured particles69 ± 0.7 nm; PDI 0.12 ± 0.009; zeta potential 8.4 ± 0.76 mVSupplementary Fig. 11a
Cell populationstdTomato-positive endothelial, non-AT2 epithelial, AT2 and immune populations are plottedSupplementary Fig. 11b; no exact percentage is inferred from bar heights
Endpoint meaningCre reporter activation documents functional deliveryNot the same endpoint as AATD mutation correction

Dual-organ base-editing evidence

Study / parameterReported evidenceSource / interpretation
Published overall resultAbstract reports 40% liver-cell and 10% lung-AT2 correction, with liver editing maintained for 32 weeksArticle abstract; combined Dual SORT treatment context
Functional outcomesAbstract reports >80% lower Z-A1AT and 89% neutrophil-elastase inhibition in lung lavage fluidRegimen-level outcomes, not standalone lipid specifications
Original dual system4A3-SC7/Cit liver LNPs were paired with 5A2-SC8/DOTAP lung LNPsSupplementary Methods and Fig. S13 identify different ionizable lipids
Updated dual systemPiZ mice received 4A3-SC7/Cit liver and 4A3-SC7/DORI lung carriers; 1.5 mg/kg each; analysis day 6; n = 3Supplementary Fig. 12; its outcomes are not conflated with the original treatment

The complete publisher main text was access-restricted during this review. Overall outcome claims above are limited to the published abstract; accessible SI tables and captions were independently checked.

Tolerability and evidence limits

Study / parameterReported evidenceSource / interpretation
Original dual regimenOrgan H&E and blood biochemistry assessed in C57BL/6J and PiZ mice, n = 3Supplementary Fig. 13; includes the 5A2-SC8 lung carrier
Updated dual regimen1.5 mg/kg Cre mRNA in each carrier; simultaneous IV treatment; 48 h analysisSupplementary Fig. 14
Safety readoutsHeart, lung, liver, spleen and kidney histology; AST, ALT, BUN and creatinineSupplementary Fig. 14 reports no signs of inflammation under those conditions
LimitsReporter-cargo tolerability does not establish every editor-cargo regimen or human safetyNo NOAEL or clinical safety claim is assigned

Original study figures

Original main Figs. 1–3: organ-selective delivery and base-editing outcomes — Original source figures.

Supplementary Figs. 1, 11–14 and Tables 1–3: formulations, cells and tolerability — Original source figures.

References and source locations

  1. Kim M, Song ES, Chen JC et al. Dual SORT LNPs for multi-organ base editing. Nature Biotechnology 44, 578–586 (2026); online 2 June 2025. DOI: 10.1038/s41587-025-02675-z.
  2. Supplementary Information: Figs. 1, 11–14; Tables 1–3 and additional methods.
CAS No.1857340-77-2
Chemical Name4A3-SC7​​
Synonyms4A3SC7​​， 4A3 SC7​​
SMILESO=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCC)C)=O
FormulaC71H131N3O16S4
M.Wt1,411.07
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Kim M, Song ES, Chen JC et al. Dual SORT LNPs for multi-organ base editing. Nature Biotechnology 44, 578–586 (2026); online 2 June 2025. DOI: 10.1038/s41587-025-02675-z.
  2. Supplementary Information: Figs. 1, 11–14; Tables 1–3 and additional methods.
F&PFormulation & PerformanceComposition, study results and referencesRead online →
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg7.0868 mL1.4174 mL708.68 μL
25 mg17.7171 mL3.5434 mL1.7717 mL
50 mg35.4341 mL7.0868 mL3.5434 mL
100 mg70.8682 mL14.1736 mL7.0868 mL
250 mg177.1705 mL35.4341 mL17.7171 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.